Figure 1



250K
200K
150K
100K
50K
0
FSC-A
10^1
10^2
10^3
10^4
10^5
FITC-A
GFP+
43,5%

Figure 2



FIG. 2A
Radium1 TcR$_{cys}$
FIG. 2B
Radium1 TcR
FIG. 2C
DMF5 TcR
FIG. 2D
Radium3 TcR
FIG. 2E
NoTcR
anti-mCD3-APC
GFP
Q1 0,036%
Q2 3,96%
Q3 94,7%
Q4 1,26%
Q1 0,495%
Q2 22,8%
Q3 75,2%
Q4 1,45%
Q1 0,410%
Q2 6,38%
Q3 92,1%
Q4 1,13%
Q1 0,139%
Q2 2,39%
Q3 96,7%
Q4 0,729%
Q1 0,119%
Q2 0,714%
Q3 96,7%
Q4 2,44%

Figure 3



FIG. 3A
NoTcR
FIG. 3B
Radium1 TcR
FIG. 3C
DMF5 TcR
Vb-APC
M1-mlt-APC
1,22%
25,0%
7,83%
Q1
0,542%
Q2
1,08%
Q3
51,0%
Q4
47,4%
Q1
0,317%
Q2
0,317%
Q3
48,6%
Q4
50,8%
Q1
3,98%
Q2
5,48%
Q3
40,2%
Q4
50,3%
GFP

Figure 4

FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D







Figure 5


GFP-A, APC-A subset
Degranulation analysis (CD107a)
GFP
T2
anti-CD3 APC
Radium-1
PE-Cy5-A subset
45,8%
% of Max
DMF-5
PE-Cy5-A subset
25,7%
% of Max
CD107a



Radium1
DMF5
EC50 = 2 nM
EC50 = 7 nM
% of maximum CD107a
100
50
0
2
1
0
-1
-2
-3
-4
log[µM peptide]

Figure 6

Figure 7




Unstimulated Cells
α-CD3 + α-CD28
pZAP70
pSLP76
pCD3zeta
pLAT
pERK

Figure 8





% of maximum CD107a
100
50
0
3
2
1
0
-1
-2
-3
log[µM peptide]
Rad-5/H
Rad-6/B
Rad-6/S
EC50 = 4 µM
EC50 = 19 µM
EC50 = 0.4 µM

Figure 9